Día Mundial del Riñón 2024: promover un acceso equitativo a la atención en salud y a la medicación óptima
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Silvariño, Ricardo | |
| dc.contributor.author | Rico-Fontalvo, Jorge | |
| dc.contributor.author | Villavicencio, Vanesa | |
| dc.contributor.author | Sánchez-Polo, Vicente | |
| dc.contributor.author | Rosa-Diez, Guillermo | |
| dc.date.accessioned | 2025-06-09T22:53:26Z | |
| dc.date.available | 2025-06-09T22:53:26Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | La enfermedad renal crónica (ERC) es una pandemia. Con variaciones regionales, afecta a 1 de cada 10 adultos (9.1-13.4%) de todo el mundo (850 millones de personas), con una prevalencia incremental cuando se analiza por décadas. Esto se adjudica a un aumento en la expectativa de vida de la población y al incremento de patologías que elevan el riesgo de ERC, principalmente hipertensión arterial, diabetes y obesidad, entre otras. La mayoría de los pacientes no necesitarán diálisis, y esto se explica (en parte) porque el desarrollo de ERC determina más probabilidad de morir a causa de una afección cardiovascular (infarto de miocardio, accidente cerebrovascular, enfermedad vascular periférica) que de ingresar a diálisis crónica. Esta mortalidad impuesta por la ERC es mundialmente reconocida. Desde 1990 es la causa de muerte por enfermedad no transmisible que más aumentó su incidencia, situándose en los primeros lugares en la tabla. Determina además elevada discapacidad. En la estimación de los años de vida ajustados a discapacidad (AVAD), es decir, el número de años perdidos por falta de salud, discapacidad o muerte prematura, para las Américas, en 2019, la ERC estaba entre las primeras causas (www.paho.org), con una tasa de AVAD de 686.1/100,000 habitantes, sin contar la carga de AVAD por enfermedad cardiovascular atribuible a la ERC. | spa |
| dc.format.mimetype | ||
| dc.identifier.doi | http://dx.doi.org/10.24875/NEFRO.M24000022 | |
| dc.identifier.issn | 24449032 (Electrónico) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/16659 | |
| dc.identifier.url | https://www.nefrologialatinoamericana.com/frame_esp.php?id=121 | |
| dc.language.iso | spa | |
| dc.publisher | Sociedad Latinoamericana de Nefrología e Hipertención | spa |
| dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | |
| dc.source | Nefrología Latinoamericana | spa |
| dc.source | Nefro Latinoam. | eng |
| dc.source | Vol. 21 No. 1, (2024) | spa |
| dc.subject | Enfermedad Renal Crónica (ERC) | spa |
| dc.title | Día Mundial del Riñón 2024: promover un acceso equitativo a la atención en salud y a la medicación óptima | spa |
| dc.title.translated | World Kidney Day 2024: promoting equitable access to health care and optimal medication | |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017:a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395:709-33. | eng |
| dcterms.references | Kovesdy CP. Epidemiology of chronic kidney disease:an update 2022. Kidney Int Suppl. 2022;12:7-11. | eng |
| dcterms.references | Hounkpatin HO, Harris S, Fraser SDS, Day J, Mindell AS, Taal MW, et al. Prevalence of chronic kidney disease in adults in England:comparison of nationally representative cross-sectional surveys from 2003 to 2016. BMJ Open. 2020;10:e038423. | eng |
| dcterms.references | Rhee CM, Kovesdy CP. Spotlight on CKD deaths —increasing mortality worldwide. Nat Rev Nephrol. 2015;11:199-200. | eng |
| dcterms.references | Nicholas SB, Kalantar-Zadeh K, Norris KC. Socioeconomic disparities in chronic kidney disease. Adv Chronic Kidney Dis. 2015;22:6-15. | eng |
| dcterms.references | Crews DC, Novick TK. Social determinants of CKD hotspots. Semin Nephrol. 2019;39:256-62 | eng |
| dcterms.references | Crump C, Sundquist J, Winkleby MA, Sundquist K. Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood:national cohort study. BMJ. 2019;365:l1346. | eng |
| dcterms.references | Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory:a paradigm shift in nephrology. Kidney Int. 1996;49:1774-7. | eng |
| dcterms.references | Blencowe H, Krasevec J, De Onis M, Black RE, An X, Stevens GA, et al. National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000:a systematic analysis. Lancet Glob Health. 2019;7:e849-60. | eng |
| dcterms.references | García-García G, Jha V. Chronic kidney disease in disadvantaged populations. Brazilian J Med Biol Res. 2015;48:377-81. | eng |
| dcterms.references | Hsu CW, Yamamoto KT, Henry RK, De Roos AJ, Flynn JT. Prenatal risk factors for childhood CKD. J Am Soc Nephrol. 2014;25:2105. | eng |
| dcterms.references | Nicholas SB. Structural predictors of renal function decline. Clin J Am Soc Nephrol. 2016;11:202. | eng |
| dcterms.references | Vart P, Powe NR, McCulloch CE, Saran R, Gillespie BW, Saydah S, et al. National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988-2016. JAMA Netw Open. 2020;3:e207932. | eng |
| dcterms.references | Hall YN, Choi AI, Himmelfarb J, Chertow GM, Bindman AB. Homelessness and CKD:a cohort study. Clin J Am Soc Nephrol. 2012;7:1094. | eng |
| dcterms.references | Liang Z, Wang W, Wang Y, Ma L, Liang C, Li P, et al. Urbanization, ambient air pollution, and prevalence of chronic kidney disease:a nationwide cross-sectional study. Environ Int. 2021;156:106752. | eng |
| dcterms.references | Correa-Rotter R, Wesseling C, Johnson RJ. CKD of unknown origin in Central America:the case for a Mesoamerican nephropathy. Am J Kidney Dis. 2014;63:506-20. | eng |
| dcterms.references | Weight TLB, Group NNW. The impact of kidney development on the life course:a consensus document for action. Nephron Clin Pract. 2017;136:3. | eng |
| dcterms.references | Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Org. 2018;96:414. | eng |
| dcterms.references | McGill R, Anwar E, Orton L, Bromley H, Williams FL, O'Flaherty M, et al. Are interventions to promote healthy eating equally effective for all?Systematic review of socioeconomic inequalities in impact. BMC Public Health 2015;15:1-15. | eng |
| dcterms.references | Mozaffarian D, Afshin A, Benowitz NL, Bittner V, Daniels SR, Franch HA, et al. Population approaches to improve diet, physical activity, and smoking habits:a scientific statement from the American Heart Association. Circulation. 2012;126:1514-63. | eng |
| dcterms.references | Luyckx VA, Tuttle KR, García-García G, Gharbi MB, Heerspink HJL, Johnson DW, et al. Reducing major risk factors for chronic kidney disease. Kidney Int Suppl. 2017;7:71-87. | eng |
| dcterms.references | Stenvinkel P, Zoccali C, Ikizler TA. Obesity in CKD —what should nephrologists know?J Am Soc Nephrol. 2013;24:1727. | eng |
| dcterms.references | Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury:a systematic review and meta-analysis. Kidney Int. 2012;81:442-8. | eng |
| dcterms.references | Radhakrishnan J, Perazella MA. Drug-induced glomerular disease:attention required!Clin J Am Soc Nephrol. 2015;10:1287. | eng |
| dcterms.references | Frass M, Strassl RP, Friehs H, Müllner M, Kundi M, Kaye AD. Use and acceptance of complementary and alternative medicine among the general population and medical personnel:a systematic review. Ochsner J. 2012;12:45-56. | eng |
| dcterms.references | Mansoor K, Kheetan M, Shahnawaz S, Shapiro AP, Tackett EP, Dial L, et al. Systematic review of nephrotoxicity of drugs of abuse, 2005–2016. BMC Nephrol. 2017;18:1-15. | eng |
| dcterms.references | Black C, Sharma P, Scotland G, McCullough K, McGurn D, Robertson L, et al. Early referral strategies for management of people with markers of renal disease:a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010;14:1-184. | eng |
| dcterms.references | Qaseem A, Hopkins Jr RH, Sweet DE, Starkey M, Shekelle P. Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease:a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159:835-47. | eng |
| dcterms.references | Komenda P, Ferguson TW, Macdonald K, Rigatto C, Koolage C, Sood MM, et al. Cost-effectiveness of primary screening for CKD:a systematic review. Am J Kidney Dis. 2014;63:789-97. | eng |
| dcterms.references | Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline:behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014 Jan;85(1):49-61. | eng |
| dcterms.references | Van Dipten C, Van Berkel S, De Grauw WJC, Nynke D, de Haan D, Brongers B, et al. General practitioners'perspectives on management of early-stage chronic kidney disease:a focus group study. BMC Fam Pract. 2018;19:1-7. | eng |
| dcterms.references | Feakins B, Oke J, McFadden E, Aronson J, Lasserson D, O'Callaghan C, et al. Trends in kidney function testing in UK primary care since the introduction of the quality and outcomes framework:a retrospective cohort study using CPRD. BMJ Open. 2019;9:e028062. | eng |
| dcterms.references | Ríos P, Sola L, Ferreiro A, Silvariño R, Lamadrid V, Ceretta L, et al. Adherence to multidisciplinary care in a prospective chronic kidney disease cohort is associated with better outcomes. PLoS One. 2022;17:e0266617. | eng |
| dcterms.references | Ríos Bruno P, Schwedt E, SoláSchnir L, Gadola L, de Souza N., La Madrid V, et al. Importancia del examen médico preventivo para el diagnóstico precoz de enfermedad renal en Uruguay:Programa Nacional de Salud Renal. Arch Med Intern. 2015;37:114-21. | spa |
| dcterms.references | Silvariño R, SoláL. Health policy for universal, sustainable and equitable kidney care. Nat Rev Nephrol. 2024;20:147-8. | eng |
| dcterms.references | Mark PB, Sarafidis P, Ekart R, Ferro CJ, Balafa O, Fernandez-Fernandez B, et al. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease:a comprehensive review by EURECA-m and ERBP working groups of ERA. Nephrol Dial Transplant. 2023;38:2444-55. | eng |
| dcterms.references | Ortiz A, Ferro CJ, Balafa O, Burnier M, Ekart R, Halimi JM, et al. Mineralocorticoid receptor antagonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. Nephrol Dial Transplant. 2023;38:10-25. | eng |
| dcterms.references | Rossing P, Baeres FMM, Bakris G, Bosch-Traberg H, Gislum M, Gough SCL, et al. The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2023;38:2041-51. | eng |
| dcterms.references | Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389:2221-32. | eng |
| dcterms.references | Neuen BL, Perkovic V, Bakris GL, Claggett BL, Fletcher RA, Arnott C, et al. Estimated lifetime benefits of combination therapy with SGLT2 inhibitors, GLP-1 receptor agonists, and non-steroidal MRAs in patients with type 2 diabetes and albuminuria. Circulation. 2023;148:A17437. | eng |
| dcterms.references | de Pouvourville G, Rossignol P, Boussahoua M, Chevalier J, Gabb PD, Poulnais R, et al. Budget impact analysis of expanding gliflozin coverage in the CKD population:a French perspective. Adv Ther 2023;40:3751-69. | eng |
| dcterms.references | McEwan P, Darlington O, Miller R, McMurray JJV, Wheeler DC, Heerspink HJL, et al. Cost-effectiveness of dapagliflozin as a treatment for chronic kidney disease:a health-economic analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022;17:1730-41. | eng |
| oaire.version | info:eu-repo/semantics/publishedVersion |